目的探索妊娠滋养细胞疾病患者的二氢嘧啶脱氢酶基因(DPYD)多态性。方法采用多聚酶链反应(PCR)一直接测序方法检测DPYD中A74G,T85C(DPYD*9),IVS14+1G→A(DPYD*2),C2303A和A2846T等5个位点的突变频率,并对DPD活性缺乏以及使用氟化嘧啶类药物出现严重不良反应的回访患者的DPYD基因中外显子4、外显子5、外显子6、外显子7、外显子8、外显子10、外显子11、外显子12、外显子13、外显子21和外显子23进行分析。结果130名妊娠滋养细胞疾病患者中,化疗组患者105名,使用含氟化嘧啶类药物治疗发生严重不良反应的回访患者25名。患者中存在DPYD*2,DPYD*9,A496G,A1627G和C2303A等位点变异,新发现A720C和A2670C 2种同义突变。化疗组患者DPYD*9等位基因发生频率为6.93%,C2303A发生频率为0.49%;未发现DPYD*2、A74G和A2846T位点变异。DPYD*2, DPYD*9,A496G,A720C,A1627G,C2303A和A2670C在DPD活性缺乏及曾出现严重不良反应的回访患者中的发生频率分别为1.14%,7.95%,3.41%,37.50%,18.1 8%,1.14%和15.91%。结论在中国妊娠滋养细胞疾病患者中发现DPYD*2, DPYD*9,A496G,A1627G等位点变异,首次在中国人群中发现C2303A,A720C和A2670C变异。DPYD*2和C2303A变异可能与DPD活性缺乏相关。
Abstract
OBJECTIVE To investigate the genetic polymorphism of dihydropyrimidine dehydrogenase gene(DPYD) in the patients with gestational trophoblastic disease.METHODS The polymerase chain reaction(PCR)-DNA sequencing technique was used to identify 5 mutation points of DPYD,including A74G,T85C(DPYD*9),IVS14+1G→A(DPYD*2),C2303A and A2846T. Exon 4,5,6,7,8,10,11,12,13,21,and 23 were also analyzed in the patients with DPD activity deficiency or suffering from severe toxicity after the administration of fluoropyrimidines.RESULTS Among 130 enrolled subjects,105 of them were treated with fluoropyrimidines-containing regime,25 were follow-up who had been suffered severe toxicity with fluoropyrimidinescontaining treatment.DPYD*2,DPYD*9,A496G,A1627G and C2303A mutations were found;while 2 novel silent mutations, A720C and A2670C,were detected.The allelic frequencies of DPYD*9 and C2303A were 6.93%and 0.49%in treatment group, respectively.The allelic frequencies of DPYD*2,DPYD*9,A496G,A720C,A1627G,C2303A and A2670C were 1.14%,7.95%, 3.41%,37.50%,18.18%,1.14%and 15.91%in the patients with DPD deficiency and follow-up group.CONCLUSION DPYD*2, DPYD*9,A496G,A720C,A1627G,C2303A and A2670C were found.DPYD*2 and C2303A may be associated with DPD deficiency.
关键词
二氢嘧啶脱氢酶 /
二氢嘧啶脱氢酶基因 /
基因多态性 /
妊娠滋养细胞疾病
{{custom_keyword}} /
Key words
dihydropyrimidine dehydrogenase /
dihydropyrimidine dehydrogenase gene /
genetic polymorphism /
gestational trophoblastic disease
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] VAN KUILENBURG A B. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil[J]. Eur J Cancer，2004，40(7)：939-950.
[2] MILLER S A，DYKES D D，POLESKY H F. A simple salting out procedure for extracting DNA from human nucleated cells[J]. Nucleic Acids Res，1988，16(3)：1215.
[3] YAMAGUCHI K，ARAI Y，KANDA Y，et al. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil[J]. Jpn J Cancer Res，2001，92(3)：337-342.
[4] HSIAO H H，YANG M Y，CHANG J G，et al. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population[J]. Cancer Chemother Pharmacol，2004，53(5)：445-451.
[5] MAEKAWA K，SAEKI M，SAITO Y，et al. Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences[J]. J Hum Genet，2007，52(10)：804-819.
[6] WEN S Y，WANG X Y，ZHANG M L，et al. Frequency detection of the known DPYD alleles in the studied subjects using oligonucleotide microarray[J]. Prog Biochem Biophys(生物化学与生物物理进展)，2004，31（11）：1031-1037.
[7] ZHANG H，LI Y M，YU C H，et al. The association between DPYD gene polymorphism and chemotherapeutic toxicity of 5-FU in gastric carcinoma and colonic carcinoma[J]. Chin J Intern Med(中华内科杂志)，2007，46（2）：103-106.
[8] SECK K，RIEMER S，KATES R，et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals[J]. Clin Cancer Res，2005，11(16)：5886-5892.
[9] JIA L，LI J H，CAI J P，et al. Survey of the polymorphism of dihydropyrimidine dehydrogenase gene in the Han nationality population [J]. J China Japan Friendship Hosp(中日友好医院学报)，2005，19（4）：202-207.
[10] WEI X，MCLEOD H L，MCMURROUGH J，et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity[J]. J Clin Invest，1996，98(3)：610-615.
[11] CHO H J，PARK Y S，KANG W K，et al. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity[J]. Ther Drug Monit，2007，29(2)：190-196.
[12] VAN KUILENBURG A B，MULLER E W，HAASJES J，et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil： frequency of the common IVS14+1G>A mutation causing DPD deficiency[J]. Clin Cancer Res，2001，7(5)：1149-1153.
[13] RAIDA M，SCHWABE W，HAUSLER P，et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls[J]. Clin Cancer Res，2001，7(9)：2832-2839.
[14] Boisdron-Celle M，Remaud G，Traore S，et al. 5-Fluorouracil-related severe toxicity： a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency[J]. Cancer Letter，2007，249(2)：271-282.
[15] VAN KUILENBURG A B，DOBRITZSCH D，MEINSMA R，et al. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure[J]. Biochem J，2002，364(Pt 1)：157-163.
[16] VAN KUILENBURG A B，HAASJES J，RICHEL D J，et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity： identification of new mutations in the DPD gene[J]. Clin Cancer Res，2000，6(12)：4705-4712.
[17] CAI L，ZHU Z. Progress in Polymorphism of Dihydropyrimidine Dehydrogenase Gene[J]. Chin Pharm J(中国药学杂志)，2008，43(9)：644-648.
[18] PLOYLEARMSAENG S A，FUHR U，JETTER A. How may anticancer chemotherapy with fluorouracil be individualized[J]. Clin Pharmacokinet，2006，45(6)：567-592.
[19] VAN KUILENBURG A B，MEINSMA R，ZOETEKOUW L，et al. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity[J]. Pharmacogenetics，2002，12(7)：555-558.
[20] OGURA K，OHNUMA T，MINAMIDE Y，et al. Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations[J]. Clin Cancer Res，2005，11(14)：5104-5111.
[21] Vreken P，Van Kuilenburg A B，Meinsma R，et al. Dihydropyrimidine dehydrogenase (DPD) deficiency： identification and expression of missense mutations C29R，R886H and R235W[J]. Hum Genet，1997，101(3)：333-338.
[22] RIDGE S A，SLUDDEN J，BROWN O，et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects[J]. Br J Clin Pharmacol，1998，46(2)：151-156.
[23] COLLIE-DUGUID E S，ETIENNE M C，MILANO G，et al. Known variant DPYD alleles do not explain DPD deficiency in cancer patients[J]. Pharmacogenetics，2000，10(3)：217-223.
[24] JOHNSONNG K，Diasio R B. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype[J]. Clin Cancer Res，2002，8(3)：768-774.
[25] HE YF，WEI W，ZHANG X，et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients[J]. J Clin Pharm Ther，2008，33(3)：307-314.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家自然科学基金资助项目(30640092)
{{custom_fund}}
